Tumor Symposium

Tumor Section Satellite SymposiumLow-grade Gliomas: Management Strategies & Innovations

SAN DIEGO, CALIFORNIA

SEPTEMBER 23-24, 2016

SAN DIEGO CONVENTION CENTER

JOINTLY PROVIDED BY THE CONGRESS OF NEUROLOGICAL SURGEONS AND THE AANS/CNS JOINT TUMOR SECTION

TUMOR SECTION SATELLITE SYMPOSIUM 12 TUMOR SECTION SATELLITE SYMPOSIUM

Experience our latest neurotechnology innovationsVisit us during the Tumor Section and the Congress of Neurosurgeons Annual Meeting

strykerneurotechnology.com/cns


Dear Colleague,

Welcome to the 2016 Tumor Section Satellite Symposium in San Diego! Over the next two days, we will explore our meeting theme, Low-grade Gliomas: Management Strategies & Innovations, and examine advancements in the treatment of adult and pediatric brain tumors. With your participation, we look forward to engaging scientific sessions covering recent clinical trials, tumor guidelines, and next-generation techniques in surgical, medical, and radiation therapies.

We are pleased to welcome keynote speakers Mitchel Berger, Hugues Duffau, and James Rutka as well as many distinguished brain tumor experts slated to present during our four General Sessions. We are also grateful to our sponsors and exhibitors, whose support helped make this meeting possible. Please remember to connect with these industry partners for lunch and afternoon breaks in the exhibit hall.

Residents, fellows, and junior attendings are invited to participate in small-group breakfast breakout sessions on Saturday morning. These are outstanding opportunities to meet senior brain tumor surgeons and learn how to set up a practice, start a lab, or seek out an academic position.

We hope to see you at the 31st Anniversary Gala Reception Friday evening at the historic US Grant Hotel. Join us in honoring the recipients of this year’s Wilson Award, Distinguished Service Award, and Parsa Mentoring Award.

Finally, we are proud to host our meeting for the first time in conjunction with the Congress of Neurological Surgeons Annual Meeting. If you plan to stay on for more great science this week, don’t forget to connect with us again at the Tumor Section sessions at the CNS Annual Meeting.

Thank you for being a part of this meeting as together we move the treatment and care of brain tumor patients forward.

Sincerely,

TABLE OF CONTENTS

Learning Objectives 2CME Information 2Program Schedule 3-15Floor Plans 16-19Exhibitors 18General Information 21-22Disclosures 23-24

SECTION CHAIR

Steven N. Kalkanis

MEETING CHAIR

Chetan Bettegowda

MEETING CHAIR

Brian V. Nahed


Symposium DescriptionThis symposium will provide an up-to-date overview of the management of low-grade tumors in adult and pediatric patients, emphasizing cutting-edge and next-generation techniques in medical, surgical, and radiation therapies. It will identify the molecular and genetic changes and efforts to target these mutations in state-of-the-art therapy.

Learning ObjectivesUpon completion of this symposium participants should be able to:• Develop treatment strategies for patients with low-grade glioma

at diagnosis and recurrence• Discuss advancements in understanding of low-grade glioma

biology and relevance to outcome• Discuss emerging surgical, medical, and radiation techniques to

achieve the best outcome

CME InformationACCREDITATION This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council of Continuing Medical Education (ACCME) through the joint providership of the Congress of Neurological Surgeons and the Tumor Section. The CNS is accredited by the ACCME to provide continuing medical education for physicians.

AMA CREDIT DESIGNATION STATEMENT

The CNS designates this live activity for a maximum of 12.75 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CLAIMING CME CREDITCME credits can be claimed through the online CME system at www.cns.org. The CME tracking system allows you to create and print a CME certificate immediately following the Tumor Section Satellite Symposium while you are still in San Diego, or from the convenience of your home or office. Log in using your last name and the email address with which you registered. You will need to enter the number of hours you are claiming for each session you attended. Physicians should only claim credit for the learning activities in which they actively participated. Upon completion of this process, your CME certificate will be sent to you via email at the email address you provided at registration.

MID-LEVEL PRACTITIONERSAttendees will receive a certificate of completion. Please contact your individual membership association and certification board to determine the requirements for accepting credits.


Program Schedule

Friday, September 23, 2016

8:00 am–5:00 pmRegistration Ballroom 6 Lobby, Upper Level

General Session 1 Room 6B, Upper Level Biology and Management of LGG

10:00–10:10 amOpening RemarksChetan Bettegowda, Steven N. Kalkanis, and Brian Nahed

10:10–10:25 am Biology of Low-grade GliomasRobert Jenkins

10:25–10:40 amDiagnosis: Medical Management/Chemotherapy and TimingSusan Chang

KEYNOTE SPEAKER 1

10:40–11:10 amMaximizing Resection for Survival/When to Operate

Mitchel S. Berger, MD, chair of neurological surgery at University of California San Francisco, is a nationally recognized expert in treating brain and spinal cord tumors and tumor-related epilepsy in adults and children. He also is a specialist in brain mapping techniques, used

to identify areas of motor, sensory and language function during surgery, and an expert in the use of the Gamma Knife for tumor treatment. He is co-director of the Adult Brain Tumor Surgery Program, director of the Brain Tumor Research Center, and director of the Center for Neurological Injury and Repair.

11:10–11:25 am Radiation TherapyJennifer Yu


11:25–11:40 am Recurrence and Progression to High-grade Houtan Noushmehr

11:40–11:55 am Clinical Trials, Targeted Therapies, MechanismsSteven Yip

11:55 am–12:10 pmJoint Section on Tumors GuidelinesJeffrey J. Olson

12:10–1:10 pm Lunch with Exhibitors in the Exhibit Hall Room 6A, Upper Level

12:10–1:10 pmSponsored Lunch Seminar Room 6B, Upper LevelControversies in Fluorescence Guided Surgery (FGS) of Gliomas: Fluorescein vs. 5-ALA

General Session 2 Room 6B, Upper Level Surgical Techniques and Adjuvant Therapy

KEYNOTE SPEAKER 2

1:15–1:45 pmMapping Intraoperatively to Maximize Resection

Hugues Duffau, MD, PhD, is professor and head of the department of neurosurgery at the University Hospital Centre of Montpellier, France. A leading expert on low-grade glioma surgery, Dr. Duffau pioneered surgery of still-conscious patients with brain tumors, resulting in a new model of the brain based on

plasticity and connectivity. He has authored more than 225 publications and four books, including Brain Mapping: From Neural Basis of Cognition to Surgical Applications, published in 2011.

1:45–1:55 pmPre-operative Imaging/fMRI

1:55–2:05 pm Intraoperative Imaging Christian Rainer Wertz

2:05–2:15 pmIntraoperative Ultrasound Francesco DiMeco

Program Schedule


2:15–2:25 pmIntraoperative 5-ALA Walter Stummer

2:25–2:35 pmFluroscent Alkylphosphocholine for Intraoperative DetectionJohn Kuo

2:35–2:45 pmIntraoperative Mass Spectroscopy Kevin Petrecca

2:45-2:55 pmRaman Spectroscopy Steven N. Kalkanis

2:55–3:05 pmIntraoperative Viral VectorsManish Aghi

3:05–3:30 pmBreak with Exhibitors Room 6A, Upper Level

Sponsored by:

3:30–5:00 pmAbstract Presentations 1: Selected Oral AbstractPresentations and Discussion Room 6B, Upper LevelModerators: Gordon Li and Pamela Jones

3:30–3:35 pmSupratotal Resection in Low-grade Gliomas: Feasibility and Clinical Impact Marco Rossi, Marco Riva, Federico Pessina, Alessandra Casarotti, Lorenzo Bello

3:35–3:40 pm The Benefit of Gross Total Resection Across Glioma Subtypes: A Comparison of Grade II/III/IV Gliomas in the Surveillance, Epidemiology, and End Results (SEER) Database Brian R. Hirshman, Ali A. Alattar, Alexander J. Schupper, Jennifer Padwal, Michael G. Brandel, Xuezhi Dong, Bob S. Carter, Clark C. Chen

3:40–3:45 pm The Value of Extent of Resection for Genetically “Favorable” and “Unfavorable” High-grade Gliomas: Analysis of the TCGA Data Shawn L. Hervey-Jumper, David Altshuler, Karam Paul Asmaro, Lisa Scarpace, Tom Mikkelsen, Steven N. Kalkanis

3:45–3:50 pm Surgical Outcomes and Complications after Reoperation for Recurrent Skull Base MeningiomasStephen T. Magill

Program Schedule


3:50–3:55 pm Atypical and Anaplastic Meningioma (AAM): Outcomes in a Population-based Study Tomas Garzon-Muvdi, Wuyang Yang, Michael Lim, Henry Brem, Judy Huang

3:55–4:00 pm Thermal Injury to Corticospinal Tract Predicts Post-operative Motor Deficits Following Laser Interstitial Thermal Therapy Mayur Sharma, Ghaith Habboub, Danilo Silva, Gene H. Barnett, Alireza M Mohammadi

4:00–4:05 pm Portable Intraoperative Computed Tomography Scan in Image-guided Surgery for Brain High-grade Gliomas: Analysis of Technical Feasibility and Impact on Extent of Tumor Resection Giuseppe Barbagallo, Stefano Palmucci, Massimiliano Visocchi, Sabrina Paratore, Giancarlo Attinà, Giuseppe Sortino, Vincenzo Albanese, Francesco Certo

4:05–4:10 pm Surgical Resection for Intracranial Malignant Teratomas: A Population-based Study Wuyang Yang, Xiaoming Rong, Tomas Garzon-Muvdi, Jose Luis Porras, Xuan Hui, Judy Huang

4:10–4:15 pm Sources of Variation Influencing Concordance Between Functional MRI and Direct Cortical Stimulation in Brain Tumor Surgery Melanie Morrison, Fred Tam, Marco Garavaglia, Gregory Hare, Michael Cusimano, Tom Schweizer, Simon Graham, Sunit Das

4:15–4:20 pm Sodium Fluorescein Facilitates Guided Sampling of Diagnostic Tumor Tissue in Non-enhancing GliomasStephen G. Bowden, Brian John Andrew Gill, Randy D’Amico, Timothy H Ung, Peter Chang, Justin A. Neira, Jorge Samanamud, Sameer A. Sheth, Guy M. McKhann, Michael B. Sisti, Peter D. Canoll, Jeffrey N. Bruce

4:20–4:25 pm Subventricular Zone Contact, but not Subgranular Zone, Corpus Callosal, nor Cortical Contact, Predicts Survival in Surgically Treated Glioblastomas Akshitkumar Mistry, Michael C. Dewan, Gabrielle A. White-Dzuro, Philip Ryan Brinson, Kyle D. Weaver, Reid C. Thompson, Rebecca Ihrie, Lola Blackwell Chambless

Program Schedule


4:25–4:30 pm Incidence of Leptomeningeal Disease Following Ventricular Entry During Resection of Supratentorial Grade IV Glioma Ben Allen Strickland, Dima Suki, Rory R. Mayer, J. Matthew Debnam, Ian E. McCutcheon, Raymond E. Sawaya, Jeffrey S. Weinberg

4:30–4:35 pm Initial Experience with an Image-guided Robotically Positioned Optical Platform for Skull Base SurgeryAmin B. Kassam, Srikant S. Chakravarthi, Juanita Celix, Sammy Khalili, Martin Corsten, Sarika Walia, Jonathan Jennings, Melanie Fukui, Richard A. Rovin

4:35–4:40 pm Cranial Chordoma: A New Classification System and Validation Harley Brito da Silva, David Straus, Manuel Ferreira Jr., Robert C. Rostomily, Jason Barber, Laligam N. Sekhar

4:40–4:45 pm Diagnostic Accuracy of PET, SPECT, and Arterial Spin-Labeling in Differentiating Tumor Recurrence from Necrosis in Cerebral Metastasis after Stereotactic Radiosurgery Clark C. Chen, Grace Y. Lai, David Hackney, Peter C. Warnke, Eric T. Wong, Bob S. Carter

4:45–4:50 pm Cochlear Radiation Dose Is Associated with Decreased Hearing Preservation for Vestibular Schwannoma Patients Treated with RadiosurgeryLawrance K. Chung, Nolan Ung, Winward Choy, Carlito Lagman, Panayiotis Emmanuel Pelargos, Brittany Voth, Alessandra A. Gorgulho, Stephen Tenn, Nader Pouratian, Tania B. Kaprealian, Michael T. Selch, Antonio DeSalles, Quinton Gopen, Isaac Yang

4:50–4:55 pm A Morphometric Survey of the Parasellar Region of over 2700 Skulls with Particular Emphasis on the Middle Clinoid Process Akshay Sharma, Gabrielle E. Rieth, Joseph E. Tanenbaum, Sunil V. Manjila, Buelent Yapicilar

4:55–5:00 pmProposing a Validated Clinical App for Predicting Unfavorable Outcomes in Patients Undergoing Craniotomy for Excision of Acoustic NeuromaPiyush Kalakoti, Jerry McLarty, Kanika Sharma, Maura Cosetti, Anil Nanda

Program Schedule


7:00–10:00 pm 31st Anniversary Gala Reception at the historic US Grant HotelPresentation of the Wilson Award, Distinguished Service Award, and Mentoring AwardComplimentary shuttle service will depart from the Marriott Marquis San Diego Marina Hotel’s lower front drive at 6:45 pm. Shuttles will return to the Marriott upon the conclusion of the event.

Saturday, September 24, 2016

7:00 am–12:00 pm Registration Ballroom 6 Lobby, Upper Level

7:00 am–5:00 pm Abstract Digital Poster Viewing in Exhibit Hall

Breakfast Breakouts for Residents, Fellows, Medical Students, and Young Attendings

8:00–9:00 amDeveloping an Independent Research Program/Lab as a Neurosurgeon Room 10, Upper LevelJohn Sampson and Manish Aghi

8:00–9:00 amNeurosurgeons as Clinical TrialInvestigators Room 11A, Upper LevelFred Barker, Michael Lim, and Michael Vogelbaum

8:00–9:00 am Finding a Neurosurgery Position as a Brain Tumor Surgeon Room 11B, Upper LevelBob Carter and Ricardo Komotar

Program Schedule


9:10–10:20 am Abstract Presentations 2: Selected Oral AbstractPresentations and Discussion Room 6B, Upper LevelModerators: Graeme Woodworth and Nduka Amankulor

9:10–9:15 am Re-visiting Racial Disparity in Outcomes Following Craniotomy for Resection of Adult Intracranial Tumors Piyush Kalakoti, Kanika Sharma, Christina Notarianni, Anil Nanda

9:15–9:20 am Racial Disparity in Short-term Outcomes and Hospital Costs in Pediatric Patients Undergoing Craniotomy for Resection of Brain Tumors: Insights from Kids’ Inpatient Database (KID) Piyush Kalakoti, Kanika Sharma, Anil Nanda, Christina Notarianni

9:20–9:25 am Early Discharge after Craniotomy Is Safe and Associated with Decreased 30-day Readmissions and Decreased Risk of DVT/PEAngela Richardson, Jagteshwar Sandhu, David McCarthy, Roxanne Mayrand, Christine Guerrero, Ricardo Jorge Komotar, Michael E. Ivan

9:25–9:30 am Differences in Patterns of Care and Prognosis in Elderly versus Non-elderly Patients with Glioblastoma Patrick Michael Flanigan, Arman Jahangiri, Ruby Kuang, Albert Truong, Sarah Choi, Alvin Chou, Annette Molinaro, Michael William McDermott, Mitchel S. Berger, Manish Kumar Aghi

9:30-9:35 am Bone Marrow Response as a Potential Biomarker of Outcomes in Glioblastoma Patients Eugene John Vaios, Brian V. Nahed, Alona Muzikansky, Amir Fathi, Jorg Dietrich

9:35–9:40 am Dosimetric Thresholds Predicting High Risk of Radionecrosis in Gamma Knife Radiosurgery for Cerebral Metastases Steven L. Gogela, Yair M. Gozal, John Thaman, Bryan Matthew Krueger, Ronald E. Warnick

Program Schedule


9:40–945 am Cochlear Function as a Novel Predictor of Hearing Preservation in Vestibular Schwannomas after Stereotactic RadiosurgeryAmparo M. Wolf, Svetlana Kvint, Aram Modrek, Carolina Gesteira Benjamin, John G. Golfinos, Joshua Silverman, Douglas Kondziolka

9:45–9:50 am Hypofractionated Radiosurgery for the Treatment of Large Brain Metastases and Post-resection Cavities Yair M. Gozal, Timothy Struve, Steven L. Gogela, Eric Wolf, McGill Brian, Michael Lamba, Luke E. Pater, John C. Breneman, Ronald E. Warnick

9:50–9:55 am VTE in Patients Undergoing Craniotomy for Brain Tumors: A NSQIP Analysis David J. Cote, Heloise H. Dubois, Aditya Vishwas Karhade, Timothy R. Smith

9:55–10:00 am Extra-pseudocapsular Dissection Technique for Growth Hormone (GH)-Secreting Pituitary Adenomas by Endoscopic Endonasal Transsphenoidal Approach Xiao-jie Lu, Qing Wang, Bing Li, Jiang-an Li, Jing Wang

10:00–10:05 am Infectious Complications after Craniotomy for Tumor: A National Surgical Quality Improvement Program Analysis Hormuzdiyar H. Dasenbrock, Sandra C. Yan, Timothy R. Smith, Elizabeth Claus, William B. Gormley, Ian F. Dunn

10:05–10:10 am Development of Persistent Mucoid Spinal Cord Mass in a Patient Following Olfactory Mucosal Stem Cell Transplantation to Treat Spinal Cord Injury Navin Sabharwal, Elizabeth Emily Bennett, Abdi S. Ghodsi, Glen Stevens, Andrew Torre Healy, Edward C. Benzel

10:10–10:20 amQuestions and Answers

10:20–10:40 pmBreak with Exhibitors Room 6A, Upper Level

Sponsored by:

Program Schedule


General Session 3: Room 6B, Upper Level

Pediatric Low-grade Tumors

10:40–10:50 am Opening RemarksChetan Bettegowda and Brian Nahed

10:50–11:10 amMedical Management of Pediatric Low-grade TumorsNathan Robison

11:10–11:30 am Radiation of Pediatric Low-grade TumorsMary McAleer

11:30 am–12:15 pm Abstract Presentations 3: Selected Oral AbstractPresentations and Discussion Room 6B, Upper LevelModerators: Peter Fecci and Kaisorn Chaichana

11:30–11:35 amTumorigenic Alterations by Mutant IDH1 in Early Gliomagenesis Aram Modrek, Themasap Khan, Danielle Golub, Michael Kader, Guoan Zhang, Jingjing Deng, Chris Bowman, Nermin Sumru Bayin, Joshua Frenster, Tenzin Lhakhang, Adriana Heguy, John Dankert, Aristotelis Tsirigos, Matija Snuderl, Thomas Neubert, Dimitris G. Placantonakis

11:35–11:40 am Integrated Prognostication of Molecular Oligodendroglioma in the Cancer Genome AtlasSameer H. Halani, Michael Nalisnik, Chad Holder, Jun Kong, Jose Enrique Velazquez Vega, Jeffrey J. Olson, Lee Cooper, Daniel J. Brat

11:40–11:45 am Epigenetic Regulation of Mesenchymal Transition by CBX6 in GBMs Yujun Wang, Gang Li, Mike Yue Chen

11:45–11:50 amHigh Dimensional Analysis of Glioblastoma Multiforme by Mass Cytometry Ahmed M. Mohyeldin, Yannick Simmone, Evan Newell, Ichiro Nakano

11:50–11:55 am A Cerebrospinal Fluid microRNA Signature for Glioblastoma Detection Johnny Akers, Valya Ramakrishnan, Ying Mao, Wei Hua, Bob S. Carter, Clark C. Chen

11:55 am–12:00 pm Three Dimensional Bioprinting of the Human Gliovascular Unit Robert Thomas Wicks, Young-Joon Seol, Goodwell Nzou, Elizabeth E. Wicks, Sang Jin Lee, Sean V. Murphy, James J. Yoo, Anthony Atala

Program Schedule


12:00–12:05 pm Confocal Laser Endomicroscopic (CLE) Characterization of the Normal Brain Cleopatra Charalampaki, Alhadi Igressa

12:05–12:10 pm Putting the Brakes on Brachyury: Identifying and Targeting a Conserved Transcriptional Network that Drives Primary and Metastatic Brain Tumor Initiation and Propagation Sagar R. Shah MS, Justin M David, Nathaniel Tippens, Ahmed Mohyeldin, Juan Carlos Martinez-Gutierrez, Sara Ganaha, Kristen Kozielski, Jordan Green, Andre Levchenko, Claudia Palena, Alfredo Quinones-Hinojosa

12:10–12:15 pm ZR30, an in vitro Synthesized EFEMP1-derived Tumor Suppressor Protein Targets MMP2, EGFR, NOTCH1, and AKT Signaling from Extracellular Compartment of Different Glioma Cell Subpopulations of Intracranial XenograftsYi-Hong Zhou, You-Xin Zhou, Yanyan Li MSc, Yuan Hu, Chuaniin Liu, Qingyue BS Wang, Xiaoxiao Han, Yong Han, Xue-Shun Xie, Xiong-Hui Chen, Eric R. Siegel, Kambiz Afrasiabi, Mark E. Linskey

12:15–1:15 pm Lunch with Exhibitors in the Room 6A, Upper LevelExhibit Hall

KEYNOTE SPEAKER 3

1:15–1:45 pm Surgery for Pediatric Low-grade Tumors

James Rutka, MD, PhD, is RS McLaughlin professor and chair of the department of surgery at the University of Toronto, and also serves on the surgical staff at the Hospital for Sick Children in the Division of Pediatric Neurosurgery. Editor-in-chief of the Journal of Neurosurgery, Dr. Rutka’s primary research and

clinical interests relate to the science and surgery of human brain tumors. His laboratory interests lie in the molecular biology of human brain tumors—specifically in the determination of the mechanisms by which brain tumors grow and invade. His recent clinical interests have centered on the surgical treatment of epilepsy in children. He has over 400 peer-reviewed publications.

Program Schedule


General Session 4 Room 6B, Upper Level

Outcomes and the Future

1:45–2:05 pm Molecular Classification and Outcomes of Low-grade GliomaAdam Resnick

2:05–2:25 pmUpcoming Targets in Low-grade GliomaAndrew Chi

2:25–2:45 pm Emerging Technologies Monitoring for Recurrence/Progression Chetan Bettegowda, Clark Chen, and Brian Nahed

2:45–3:00 pmParsa Mentoring Award Steven N. Kalkanis

3:00–3:35 pm Break with Exhibitors Room 6A, Upper Level

3:35–5:00 pm Abstract Presentations 4: Selected Oral AbstractPresentations and Discussion Room 6B, Upper LevelModerators: Sunit Das and Chris Farrell

3:35–3:40 pm Immune Checkpoint Blockade as a Potential Therapeutic Target: Surveying CNS MalignanciesSarah Tamara Garber, Yuuri Hashimoto, Shiao-Pei Weathers, Joanne Xiu, Zoran Gatalica, Roel Verhaak, Shouhao Zhou, Gregory N. Fuller, Mustafa Khasraw, John Degroot, Sandeep Reddy, David Spetzler, Amy B. Heimberger

3:40–3:45 pm Peripheral Lymphocytic Immune Checkpoint Landscape in Primary and Recurrent GlioblastomaLeonel Ampie, Winward Choy, Jonathan Balquiedra Lamano, Joseph D. DiDomenico, Kartik Kesavabhotla, Orin Bloch

3:45–3:50 pm Treatment with Hypomethylating Agent Decitabine Can Reverse Immune Escape by Isocitrate Dehydrogenase Mutant Gliomas Xiaoran Zhang MS, Aparna Rao, Christopher P. Deibert, Wajin Jason Kim, Alexander Pomerantz, Nduka M. Amankulor

3:50–3:55 pm CCL21 Vault Nanoparticle as an Immunotherapeutic for Glioblastoma Panayiotis Emmanuel Pelargos, Brittany Voth, Nikhilesh Bhatt, Carlito Lagman, Nolan Ung, Winward Choy, Isaac Yang

Program Schedule


3:55–4:00 pmSulforaphane Inhibits the Formation of Glioma Induced Myeloid Derived Suppressor Cells and Reduces Myeloid PDL1 ExpressionRavi Kumar, Ian F. Parney

4:00-4:05 pmCraniotomy for Intracranial Melanoma Metastases Offers a Bridge Towards Enhancing Efficacy of Checkpoint Inhibitor TherapyChristopher Alvarez-Breckenridge, Corey Gill, Mia Bertalan, Daniel P. Cahill, Ryan Sullivan, Priscilla Brastianos

4:05–4:10 pmValidation of the Programmed Death-Ligand 1 Antibody Clone 28-8 for Immunohistochemistry in Brain Tumor PatientsArnold Obungu, Saman Sizdahkhani, Graham Lobel, Nancy A. Edwards, Edjah K. Nduom

4:10–4:15 pmSynergistic Anti-tumor Effect with Indoleamine 2,3-dioxygenase Inhibition and Temozolomide in a Murine Glioma ModelHiroyuki Kinouchi, Mitsuto Hanihara, Tomoyuki Kawataki

4:15–4:20 pmA Potential New Adjunct to Temozolomide Therapy in GlioblastomaGary R. Simonds, Cara Rogers

4:20–4:25 pmCombined Multimodality Treatment with Hypoxia-activated Prodrug TH-302 and XRT Results in Enhanced Antitumor Efficacy in Preclinical Malignant Meningioma Mouse ModelAsif Maknojia, Vaibhav Patel, Michael Garcia, Dave Cavazos, Courtney Bosse, Aleksandra Gruslova, Niko Papanikolaou, Andrew Brenner, John Robert Floyd

4:25–4:30 pmPreclinical Study and Translational Application of Concurrent Radiotherapy and Valproic Acid for Intracranial Hemangioblastomas in Sporadic HemangioblastomatosisGautam U. Mehta, Saman Sizdahkhani, Charlton Smith, Christina Hayes, DeeDee Smart, Prashant Chittiboina

Program Schedule


4:30–4:35 pm Phosphatase 2A Inhibitor, LB100, Sensitizes Malignant Meningioma Cells to Radiation by Autophagy Inhibition Sze Chun Winson Ho, Saman Sizdahkhani, Anita Tandle, Dragan Maric, Deric M. Park, Zhengping Zhuang, John D. Heiss

4:35–4:40 pm Modulation of Radiation Induced Cell Death in Glioma via Cadherin-mediated Tumor Microenvironment Alteration Christopher Paul Cifarelli

4:40–4:45 pm Engineering Primary Patient-derived Adipose Mesenchymal Stem Cells (hMSCs) with Nanoparticles: An Autologous “Trojan Horse” for the Intraoperative Treatment of Brain CancerRawan Alkharboosh, Kristen Kozielski, Jordan Green, Alfredo Quinones-Hinojosa

4:45–4:50 pm Self-assembling Camptothecin Hydrogel: A Local Treatment for Brain TumorsMontserrat Anilu Lara-Velazquez, Paula Schiapparelli, Ran Lin, Pengcheng Zhang, Hao Su, Hugo Guerrero Cazares, Honggang Cui, Alfredo Quinones-Hinojosa

4:50–4:55 pmDisulfiram Sensitizes Glioblastoma to Abraxane and Temozolomide Treatment Through Inhibition of MGMT and Aldehyde DehydrogenaseGeorge C. Bobustuc, Deborah L. Donohoe, Richard A. Rovin, Amin B. Kassam, Santhi D. Konduri

4:55–5:00 pm Acid Ceramidase is a Novel Drug Target Against Multiple Pediatric Brain Tumors Ninh Doan, Wade M. Mueller, Shama Mirza, Kathleen M. Schmainda, Mona Al-Gizawiy, Andrew Montoure, Ha Nguyen

Program Schedule


Convention Floor Plan Convention Center Overview

6ATumor Exhibit Hall

Ballroom 6 Lobby Tumor Registration

10, 11A, 11BBreakfast Breakouts

Convention Center Upper Level

San Diego Convention Center

GROUND LEVELRegistration | Saturday to Wednesday

ExhibitHallC | Monday to Wednesday | General Scientific Sessions

Monday & Tuesday | Operative Neurosurgery Sessions

Monday | Clinical Trials Update Sessions

CNS EXHIBIT HALL (Exhibit Halls A & B)

REGISTRATION ENTRANCE from Marriott Marquis San Diego Marina Hotel

CNS HOTEL SHUTTLES

OVERVIEW

UPPER LEVEL MEETING ROOMS/BALLROOMS/SAILS PAVILIONMEZZANINE LEVEL MEETING ROOMS

GROUND LEVEL EXHIBIT HALLS

PARKING STRUCTURE

UNDERGROUNDPARKING GARAGE 2 LEVELS

SAN DIEGO BAY

FIRST

AVEN

UE

FIFT

H A

VEN

UE

FRO

NT

STRE

ET

WEST HARBOR DRIVE

GASLAMP QUARTER

SAN DIEGO BAY

CONVENTION WAY

98#CNS2016


Convention Floor Plan Convention Center Overview

6BTumor General Session & Abstract Oral Presentations

6ATumor Exhibit Hall

5BSpeaker Ready Room

San Diego Convention Center

GROUND LEVELRegistration | Saturday to Wednesday

ExhibitHallC | Monday to Wednesday | General Scientific Sessions

Monday & Tuesday | Operative Neurosurgery Sessions

Monday | Clinical Trials Update Sessions

CNS EXHIBIT HALL (Exhibit Halls A & B)

REGISTRATION ENTRANCE from Marriott Marquis San Diego Marina Hotel

CNS HOTEL SHUTTLES

OVERVIEW

UPPER LEVEL MEETING ROOMS/BALLROOMS/SAILS PAVILIONMEZZANINE LEVEL MEETING ROOMS

GROUND LEVEL EXHIBIT HALLS

PARKING STRUCTURE

UNDERGROUNDPARKING GARAGE 2 LEVELS

SAN DIEGO BAY

FIRST

AVEN

UE

FIFT

H A

VEN

UE

FRO

NT

STRE

ET

WEST HARBOR DRIVE

GASLAMP QUARTER

SAN DIEGO BAY

CONVENTION WAY

98#CNS2016


Exhibit Hall Floor Plan

EXHIBITOR BOOTH

Arbor Pharmaceuticals 307, 313

Brainlab 305

BioD, LLC 306

Carl Zeiss 311

Medtronic 309

Monteris Medical 304

Stryker 308

Exhibitors

Ballroom 6-Lobby


Exhibit Hall Floor Plan

Thank you Corporate SupportersSilver Supporter

Carl Zeiss

Bronze Supporters

Arbor Pharmaceuticals

Medtronic

Stryker

BioD, LLC

Monteris Medical

Ballroom 6-Lobby

TUMOR SECTION SATELLITE SYMPOSIUM 21PP-GLD-US-0142

Vigilant ObservatIon of GlIadeL

WAfer ImplaNT (VIGILANT)

Registry: A Multicenter,

Observational Registry to

Collect Information on the

Safety and Effectiveness

of Gliadel® Wafer

(Carmustine Implant) Used in

Usual Medical Practice

Sponsored by Arbor Pharmaceuticals, LLC

For more information aboutthe VIGILANT Registry,

or if you are interested inparticipating, please contact

the study team at:

[email protected] (phone/fax)

ClinicalTrials.gov #NCT02684838

Visit Arbor Medical AffairsBooth 313 to learn more about

TUMOR SECTION SATELLITE SYMPOSIUM 21PP-GLD-US-0142

Vigilant ObservatIon of GlIadeL

WAfer ImplaNT (VIGILANT)

Registry: A Multicenter,

Observational Registry to

Collect Information on the

Safety and Effectiveness

of Gliadel® Wafer

(Carmustine Implant) Used in

Usual Medical Practice

Sponsored by Arbor Pharmaceuticals, LLC

For more information aboutthe VIGILANT Registry,

or if you are interested inparticipating, please contact

the study team at:

[email protected] (phone/fax)

ClinicalTrials.gov #NCT02684838

Visit Arbor Medical AffairsBooth 313 to learn more about

General Information

Americans with Disabilities Act

The Tumor Section wishes to take those steps to ensure that no individual with a disability is excluded, denied services, segregated, or otherwise treated differently than other individuals because of the absence of auxiliary aids or services. If you require any of the auxiliary aids or services identified in the Americans with Disabilities Act in order to attend any program, please send your requirements directly to the CNS Meetings Department at [email protected] or by calling 847-240-2500.

AttireProfessional attire is appropriate for the meeting and in the Exhibit Hall. Professional /dressy attire is appropriate for the Friday, September 23, Gala Reception and Dinner.

Meeting AppConveniently manage your schedule, browse program content, and keep up with what’s going on. Download the free EventPilot app from the Apple or Google Play store. Log in with the event code:

TUMOR16

WiFi Service

For your convenience, complimentary Wi-Fi service is provided by the CNS throughout the San Diego Convention Center wherever Tumor Section events are being held.

Network Name: cns ConferenceConference Passcode: cns2016


DisclaimerThe material presented at the 2016 Tumor Section Satellite Symposium has been made available by the Tumor Section for educational purposes only. The material is not intended to represent the only, nor necessarily the best, method or procedure appropriate for the medical situations discussed, but rather is intended to present an approach, view, statement, or opinion of the faculty which may be helpful to others who face similar situations.

Neither the content (whether written or oral) of any course, seminar, or other presentation in the program, nor the use of a specific product in conjunction therewith, nor the exhibition of any materials by any parties coincident with the program, should be construed as indicating endorsement or approval of the views presented, the products used, or the materials exhibited by the Tumor Section or by its Committees or Affiliates.

The Tumor Section disclaims any and all liability for injury or other damages resulting to any individual attending the meeting, and for all claims which may arise out of the use of the techniques demonstrated therein by such individuals, whether these claims shall be asserted by physicians or any other person.

No reproductions of any kind, including audiotapes and videotape, may be made of the presentations at the Tumor Section Satellite Symposium. The Tumor Section reserves all of its rights to such material, and commercial reproduction is specifically prohibited.

Onsite Registration Hours

Friday, September 23 8:00 am–5:00 pm

Saturday, September 24 7:00 am–12:00 pm

Exhibit Hall Hours

Friday, September 23 12:00 pm–5:00 pm


Admittance to the Exhibit Hall is by Tumor Section Satellite Symposium name badge only. Children under the age of 18 are not allowed in the Exhibit Hall.

SmokingThe San Diego Convention Center and official Tumor Section Satellite Symposium hotels are non-smoking facilities.

Speaker Ready RoomAll speakers and abstract presenters should visit the Speaker Ready Room (Room 5B) at the San Diego Convention Center a minimum of 1 hour prior to their presentations.

Friday, September 23 8:00 am–5:30 pm



Disclosures

The Congress of Neurological Surgeons controls the content and production of this CME activity and attempts to assure the presentation of balanced, objective information. In accordance with the Standards for Commercial Support established by the Accreditation Council for Continuing Medical Education, speakers are asked to disclose any relationship they have with commercial companies which may be related to the content of their lecture.

Speakers who have disclosed a relationship with commercial companies whose products may have a relevance to their presentation are listed below. Faculty who are also considered Planners are designated by P. Disclosures are current as of August 16, 2016.

Positional Interest Codes1 CEO2 Consultant3 Director4 Editorial Board5 Employee

Gene H. BarnettConsulting Agreement - Monteris Medical Company (2)

Edward C. Benzel, MDConsulting Agreement - Axiomed (2)

Daniel P. Cahill, MDConsulting Agreement - Merck (2)

Susan Chang, MD Consulting Agreement - Edge Therapeutics (2), Neonc (2), Tocagen (2), Other - Agios (6), Novartis (6), Quest (6), Roche (6)

Clark C. Chen, MD, PhDConsulting Agreement – Monteris (2), MRI Intervention (2), Tocagen (2),

Mike Yue Chen, MD, PhDConsulting Agreement – Globus (2): Royalty – Globus Medical (2) Ownership Interest – Medplate (7); Grants – Orthofix ((N/A)

John G. Golfinos, MDConsulting Agreement - Viewray (6)

William B. Gormley, MDConsulting Agreement - Codman (6)

Amy B. Heimberger, MDConsulting Agreement - Caris Life Sciences (2)

Michael E. Ivan, MD, MBSConsulting Agreement - Medtronic (2)

Amin B. Kassam, MDConsulting Agreement – Synaptive Medical (2)

Ricardo Jorge Komotar, MD Consulting Agreement - Medtronic (2)

Gordon Li, MDConsulting Agreement - Medtronic (2)

Michael Lim, MD Consulting Agreement - accuray (2), bms (2), Izi (2), Stryker (2), Grants - Accuray (6), Aegenus (6), Altor (6), Celldex (6), Immunocellular (6)

Jeffrey J. Olson, MD Grants - Roche (6)

Kevin Petrecca, BSc, MD, PhDOwnership Interest - ODS Medical (8)

Dimitris G. Placantonakis, MD, PhDOther – Tocagen, Inc. (2)

Laligam N. Sekhar, MDOther -Spisurgical (6), Viket Medical, Inc. (6)

Walter Stummer, MDConsulting Agreement - Medac (2), Nxpharmagene (2), Zeiss (2)

Michael A. Vogelbaum, MD, PhD Honoraria - Neuralstem, Inc. (6), Pharmicokinesis (6), Ownership Interest - Infuseon Therapeutics (7), Royalty - Infuseon Therapeutics (7)

Buelent Yapicilar, MDGrants - Stryker (6)

Yi-Hong Zhou, PhDOwnership Interest – Patent on protein and Nucleotide Sequences of ETSP ((8) Nothing to

6 N/A7 Officer8 Owner9 Trustee

24 TUMOR SECTION SATELLITE SYMPOSIUM

Kambiz Afrasiabi, MD Manish Kumar Aghi, MD, PhDJohnny AkersAli A. Alattar, BSVincenzo AlbaneseMona Al-Gizawiy, PhD Rawan Alkharboosh, MSDavid Altshuler, MDNduka M. Amankulor, MD Leonel Ampie, BSKaram Asmaro, MDAnthony Atala, MDGiancarlo Attinà Giuseppe Barbagallo, MDJason Barber, MS Frederick Barker, MDLorenzo Bello, MDCarolina Gesteira Benjamin, MDElizabeth Emily Bennett, MD, MSDavid BergP Mitchel S. Berger, MD Mia Bertalan, BS Chetan Bettegowda, MD, PhDP Nikhilesh BhattOrin Bolch, MDGeorge C. Bobustuc, MDCourtney BosseStephen G. Bowden, BMChris BowmanMichael G. Brandel, BADaniel J. BratPriscilla Brastianos, MDChristopher Alvarez-BreckenridgeHenry Brem, MDJohn C. Breneman, MDAndrew Brenner, MDPhilip Ryan Brinson, BS George G. Bowden, BMMichael G. Brandel, BA Harley Brito da Silva, MDJeffrey N. Bruce, MD Thomas Brucke Peter D. Canoll, MD, PhD Bob S. Carter, MD, PhD Alessandra CasarottiDave CavazosJuanita Celix, MDFrancesco Certo, MDSrikant S. ChakravarthiLola Blackwell Chambless, MDPeter Chang, BA Cleopatra Charalampaki, MD, PhDXiong-Hui Chen, MD Andrew Chi, MDPrashant Chittiboina, MD, MPHSarah ChoiAlvin ChouWinward Choy, BALawrence K. Chung, BSChristopher P. Cifarelli, MD, PhDElizabeth Claus, MDLee CooperMartin Corsten, MDMaura Cosetti David J. Cote, BSHonggang CuiMichael Cusimano, MDRandy D’Amico, MDDavid J. Daniels, MD, PhDJohn DankertSunit Das, MD, PhD Hormuzdiyar H. Dasenbrock, MDJustin M. David, PhDTristan de Mooij, MDJ. Matthew Debnam, MDJohn DegrootChristopher P. DeibertJingjing DengAntonio DeSalles, MD, PhDMichael C. Dewan, MDJoseph D. DiDomenico, BSJorg Dietrich, MD, PhD Francesco DiMeco, MDNinh Doan, MD, PhDXuezhi Dong, BADeborah L. Donohoe, BSHeloise H. DuboisHugues Duffau, MD, PhD Ian F. Dunn, MDNancy A. Edwards, BAChristopher FarrellAmir FathiPeter Fecci, MD, PhDManuel Ferreira, Jr. Patirick Michael Flanigan, BSJohn Robert Floyd, MDJoshua FrensterMelanie Fukui, MDGregory N. Fuller, MD, PhDSara Ganaha, MDMarco Garavaglia Sarah Tamara Garber, MDMichael GarciaCorey Gill, BS Tomas Garzon-Muvdi, MD, MSZoran GatalicaAbdi S. Ghodsi, MDBrian John Andrew Gill Steven L. Gogela, MDDanielle GolubQuinton Gopen, MDAlessandra A. Gorgulho, MD Yair M. Gozal, MD, PhDSimon Graham, PhDJordan GreenAleksandra Gruslova

Christine GuerreroHugo Guerrero Cazares, MD, PhDGhaith Habboub, MDDavid Hackney Sameer H. Halani, BA, MSXiaoxiao Han, MDYong HanMitsuto Hanihara, MD, PhD Gregory HareYuuri HashimotoChristina HayesAndrew Torre Healy, MDMichele HeaphyP

Adriana HeguyJohn D. Heiss, MDShawn L. Hervey-Jumper, MDStacy HilsabeckP Brian R. Hirshman, MD, MSSze Chun Winson Ho, MDChad HolderYuan Hu, MDWei HuaJudy Huang, MDXuan Hui, MD, ScMAlhadi Igressa, MDRebecca IhrieArman Jahangiri, BSRobert JenkinsJonathan Jennings, MDAaron Johnson, PhDMichael Kader Piyush Kalakoti, MDSteven N. Kalkanis, MDP

Tania B. KaprealianAditya Vishwas Karhade, BETomoyuki Kawataki, MD, PhDKartik KasavabhotlaKathleen KennedyP

Sammy Khalili, MDThemasap KhanMustafa KhasrawWajin Jason KimHiroyuki Kinouchi, MD, PhDSanthi D. KonduriDouglas Kondziolka, MD, MSc,

FRCS(C)Jun KongKristen KozielskiBryan Matthew Krueger, MDRuby Kuang, MSRavi Kumar, MDJohn S. Kuo, MD, PhD, FACSSvetlana Kvint, MDCarlito Lagman, MDGrace Y. Lai, MD, PhDJonathan B. Lamano, MSMichael Lamba Montserrat Aniul Lara-VelazquezSang Jin LeeMichele LengermanP

Andre LevchenkoTenzin LhakhangBing LiGang LiJiang-an LiYanyan Li, MScRan LinMark E. Linskey, MDGraham Lobel Xiao-jie Lu, MDStephen T. Magill, MD, PhDAsif Maknojia, MDSunil V. Manjila, MBBSSydney ManolaP

April MartinP

Ying Mao, MDDragan MaricJuan Carlos Martinez-GutierrezRory R. Mayer, MDRoxanne MayrandDavid McCarthyIan E. McCutcheon, MDMichael William McDermott, MDBrian McGill, MSGuy M. McKhann, MDJerry McLarty Gautam U. Mehta, MDTom Mikkelsen, MDShama Mirza, PhD Akshitkumar Mistry, MDAram ModrekAlireza M. Mohammadi, MD Ahmed Mohyeldin, MDAnnette Molinaro, MA, PhDAndrew Montoura, MD Melanie Morrison, BSWade M. Mueller, MDSean V. Murphy, PhDAlona Muzikansky Brian V. Nahed, MDP Ichiro Nakano, MD, PhDMichael NalisnikAnil Nanda, MD Edjah K. Nduom, MDHoutan NoushmehrJustin A. Neira, BAThomas Neubert, PhDEvan NewellHa Nguyen, MDChristina Notarianni, MDGoodwell Nzou, BSArnold ObunguJennifer Padwal, BSClaudia Palena, PhDStefano PalmucciNiko Papanikolaou

Sabrina ParatoreDeric M. ParkIan F. Parney, MD, PhDVaibhav M. Patel, MD, BSLuke E. Pater, MD Panayiotis Emmanuel Pelargos,

BAFederico PessinaTimothy E. Peterson, MScAlexander PomerantzJose Luis PorrasNader Pouratian, MD, PhDAlfredo Quinones-Hinojosa, MDValya RamakrishnanAparna Rao, PhDSandeep ReddyAngela Richardson, MD, PhDGabrielle E. Rieth, BS, MSMarco Riva, MD Cara RogersXiaoming Rong, MD Marco Rossi, MDRobert C. Rostomily, MDRichard A. Rovin, MD James T. Rutka, MD, PhD,

FRCS(C), FACS Navin C. SabharwalJorge Samanamud John H. Sampson, MD, PhD,

MHSc, MBA Nader Sanai, MDJagteshwar SandhuRaymond E. Sawaya, MDLisa ScarpacePaula SchiapparelliKathleen M. Schmainda, PhDAlexander J. SchupperTom Schweizer, PhDMichael SelchYoung-Joon Seol, PhD Sagar R. Shah, MSMayur Sharma, MD, MChSameer A. Sheth, MD, PhDRegina ShupakP

Eric R. Siegel MScDanilo Silva, MDJoshua Silverman, MDYannick SimmoneGary R. Simonds, MDMichael B. Sisti, MDSaman SizdahkhaniDeeDee SmartCharlton SmithTimothy R. Smith, MD, PhD, MPHMatija SnuderlGiuseppe SortinoDavid SpetzlerDeanne StarrP

Glen Stevens, DO, PhDDavid Straus, BARyan Sullivan, MD Ben Allen Strickland, MDTimothy Struve, MDHao Su, PhDDima Suki, PhDNermin Sumru Bayin, MSFred TamAnita TandleJoseph E. Tanenbaum, BAStephen TennJohn ThamanReid C. Thompson, MDNathaniel TippensAlbert TruongAristotelis Tsirigos, PhDNolan Ung, BSTimothy H. Ung, MDEugene John Vaios, MAJose Enrique Velazquez VegaRoel VerhaakMassimiliano VisocchiBrittany Voth, BSSarika Walia, MDJing WangQing WangQingyue Wang, BSYujun Wang, PhDRonald E. Warnick, MDPeter C. Warnke, MDShiao-Pei WeathersKyle D. Weaver, MDJeffrey S. Weinberg, MDChristian Rainer-WertzGabrielle A. White-Dzuro, MDElizabeth E. Wicks Robert Thomas Wicks, MDAmparo M. Wolf, MD, PhDEric Wolf, MSEric T. Wong, MDGraeme Woodworth, MDXue-Shun Xie, BScJoanne XiuSandra C. Yan, BS, BAIsaac Yang, MD Wuyang Yang, MD, MSStephen Yip, MDJames J. Yoo, MD, PhD Jennifer Yu Guoan ZhangPengcheng Zhang, PhD Xiaoran Zhang, MD, MSShouhao Zhou, MD, PhDYou-Xin ZhouZhengping Zhuang

DisclosuresNothing to Disclose

24 TUMOR SECTION SATELLITE SYMPOSIUM

FLOSEAL Hemostatic Matrix IndicationFLOSEAL Matrix is indicated in surgical procedures (other than ophthalmic) as an adjunct to hemostasis when control of bleeding by ligature or conventional procedures is ineffective or impractical.

Important Risk Information for FLOSEAL MatrixDo not inject or compress FLOSEAL Matrix into blood vessels. Do not apply FLOSEAL Matrix in the absence of active blood � ow, e.g., while the vessel is clamped or bypassed, as extensive intravascular clotting and even death may result.Do not use FLOSEAL Matrix in patients with known allergies to materials of bovine origin. Do not use FLOSEAL Matrix in the closure of skin incisions because it may interfere with the healing of the skin edges.FLOSEAL Matrix contains Thrombin made from human plasma. It may carry a risk of transmitting infectious agents, e.g., viruses, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent.FLOSEAL Matrix is not intended as a substitute for meticulous surgical technique and the proper application of ligatures or other conventional procedures for hemostasis.Excess FLOSEAL Matrix (material not incorporated in the hemostatic clot) should always be removed by gentle irrigation from the site of application.FLOSEAL Matrix swells by approximately 10% to 20% after product is applied. Maximum swell volume is achieved within about 10 minutes.The safety and effectiveness of FLOSEAL Matrix has not been established in children under 2 years of age and pregnant women.Do not use air to remove residual FLOSEAL Matrix from Applicator tip. The Applicator tips should not be cut. Do not use FLOSEAL Matrix on bone surfaces where adhesives, such as methylmethacrylate or other acrylic adhesives, will be required to attach a prosthetic device.Rx Only. For safe and proper use of this device, refer to the full Instructions for Use.

Study design Prospective, randomized, multi-center trial comparing FLOSEAL Matrix with GELFOAM® Hemostat+thrombin in stopping intraoperative bleeding during spinal surgery. Four centers randomized 127 patients, 21 years of age or older. Randomization occurred after a bleeding lesion requiring a topical hemostatic agent was identi� ed. The primary endpoint was hemostasis success for the � rst treated bleeding site. There was no difference in the adverse event pro� le between the two groups.2

References: 1. FLOSEAL Hemostatic Matrix Instructions for Use. Hayward, CA: Baxter Healthcare Corporation. 2. Renkens KL Jr, Payner TD, Leipzig TJ, et al. A multicenter, prospective, randomized trial evaluating a new hemostatic agent for spinal surgery. Spine. 2001;26:1645-1650.

Baxter and Floseal are registered trademarks of Baxter International Inc. Gelfoam is a registered trademark of Pharmacia & Upjohn Company LLC, and is used under license.

USMP/9/16-0019 07/2016

THE POWER OF FAST

ACHIEVES HEMOSTASIS TWICE AS FASTAS GELFOAM® HEMOSTAT + THROMBIN IN SPINE SURGERY1

(Median time to hemostasis: 1.5 minutes compared to 3.0 minutes)1,2

For more information or to place an order call 1-888-229-0001

NOTE: Prints 4/C process. All linked images are production ready.Mechanical Specs: PDF/X-1a:2001Trim Size: 4" x 9.5" with a ¼" bleed

BBS6-016_USMP9160019_Floseal_AANS_CNS_Program_Book_Ad.indd 1 8/3/16 11:15 AM

DO YOU OWN THE MOMENT?

Visit us at booth 307

Gliadel® is manufactured by Eisai Inc. for Arbor Pharmaceuticals, LLC.Gliadel® is a registered trademark of Eisai Inc ©2015 Arbor Pharmaceuticals, LLC.PP-GLD-US-0049 All rights reserved.

Tumor Symposium

Documents